Pazopanib/Pazopanib (Pazopanib) launch time

Pazopanib/Pazopanibonyear10month19day FDAapproved for marketing, and pazopanib was launched in China on March 3, 2017. Pazopanib/PazopanibPazopanib is an anti-cancer drug sold globally by Novartis under the trade name Votrient. It is a potent and selective multi-target receptor tyrosine kinase inhibitor that blocks tumor growth and inhibits angiogenesis. It has been approved by numerous regulatory agencies around the world for the treatment of renal cell carcinoma (RCC) and soft tissue sarcoma.

The most common side effects of pazopanib are nausea, vomiting, diarrhea, hair color changes, hypertension, loss of appetite, and hyperglycemia, Hypoglycemia and electrolyte abnormalities (including hypocalcemia, Hypomagnesemia, Hypophosphatemia), laboratory abnormalities, edema, hair loss or discoloration, taste changes, abdominal pain, rash, fatigue and bone marrow suppression etc.

Pazopanib is an oral multi-target tyrosine kinase receptor inhibitor with anti-tumor activity. Pazopanib inhibits vascular endothelial growth factor receptor (VEGFR)-1, -2 and -3 span>, platelet-derived growth factor receptor (PDGFR), and ckit, which may lead to inhibition of angiogenesis in tumors in which these receptors are upregulated. There are generic drugs in Bangladesh, and the retail price of Bangladesh Yaopin International Pharmaceuticals is about 200mg 30 tablets 600 yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0

xa0